SCHEMBL4325645

SCHEMBL4325645

N#Cc1cc(-c2cc(-c3cccnc3)no2)ccc1F

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 12/20 0.49
CYP2C9 P11712 12/20 0.49
CYP2C19 P33261 12/20 0.49
CYP1A2 P05177 9/20 0.47
CYP2D6 P10635 8/20 0.47
CHRNB2 P17787 2/20 0.46
CHRNA5 P30532 2/20 0.46
CHRNA4 P43681 2/20 0.46
CYP2E1 P05181 1/20 0.44
CYP2A6 P11509 1/20 0.44
CYP2B6 P20813 1/20 0.44
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 2/20 0.42
GAA P10253 2/20 0.42
HPGD P15428 2/20 0.42
GLA P06280 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
SQOR Q9Y6N5 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4319873 0.84 CHRNB2 (0.63) CYP3A4CYP2C9CYP2C19CYP1A2CYP2D6
SCHEMBL4324727 0.83 GRM5 (0.41) CYP3A4CYP2C9CYP2C19CYP1A2CYP2D6
SCHEMBL4324681 0.81 CYP2C9 (0.49) CYP3A4CYP2C9CYP2C19CYP1A2CYP2D6
SCHEMBL4325945 0.81 CYP3A4 (0.66) CYP3A4CYP2C9CYP2C19CYP1A2CYP2D6
SCHEMBL1422717 0.81 CHRNB2 (0.73) CHRNB2CHRNA5CHRNA4KDM4EALDH1A1
SCHEMBL4331170 0.80 CYP3A4 (0.67) CYP3A4CYP2C9CYP2C19CYP1A2CYP2D6
SCHEMBL4316626 0.79 CYP2C19 (0.64) CYP3A4CYP2C9CYP2C19CYP1A2CYP2D6
SCHEMBL4318440 0.78 CYP3A4 (0.62) CYP3A4CYP2C9CYP2C19CYP1A2CYP2D6
SCHEMBL4315894 0.78 CYP2C19 (0.51) CYP3A4CYP2C9CYP2C19CYP1A2CYP2D6
SCHEMBL4325908 0.78 CYP2C9 (0.65) CYP3A4CYP2C9CYP2C19CYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009149135-A1 BIS (HETERO ) ARYL SUBSTITUTED ISOXAZOLES FOR USE AS NEURONAL NICOTINIC RECEPTOR MODULATORS ABBOTT LABORATORIES (US) 2009-12-10 WO claimed
US-20090306096-A1 Novel Isoxazoles and Methods of Use Thereof ABBOTT LABORATORIES (US) 2009-12-10 US claimed
US-8383658-B2 Isoxazole based neuronal nicotinic receptor ligands and methods of use ABBOTT LABORATORIES (US) 2013-02-26 US disclosed
US-20090306096-A1 Novel Isoxazoles and Methods of Use Thereof ABBOTT LABORATORIES (US) 2009-12-10 US disclosed
WO-2009149135-A1 BIS (HETERO ) ARYL SUBSTITUTED ISOXAZOLES FOR USE AS NEURONAL NICOTINIC RECEPTOR MODULATORS ABBOTT LABORATORIES (US) 2009-12-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306096-A1 Novel Isoxazoles and Methods of Use Thereof XDH, PRDX5, CYP4X1 CYP3A4 44/4885CYP2C9 136/4885CYP2C19 105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.